Edarbyclor
Product Images NDC 75929-230

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Edarbyclor (NDC 75929-230). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pharma Packaging Solutions, Llc Dba Tjoapack Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle1 (Bottle1)

Label for Edarbyclor 40 mg / 25 mg tablets, containing azilsartan medoxomil and chlorthalidone. The label indicates Rx only status and states each tablet contains 42.68 mg azilsartan kamedoxomil equivalent to 40 mg azilsartan medoxomil, plus 25 mg chlorthalidone. The package contains 30 tablets and includes storage instructions and tamper-evident warnings. The product is manufactured for Azurity and by Takeda in Ireland.*

FDA Label Image

Figure 1.a (Edarbyclor 01)

A line chart comparing the percentage of patients achieving systolic blood pressure under 140 mmHg based on baseline systolic BP (mmHg). It shows three lines for Edarbyclor 40/25 mg, Azilsartan medoxomil 80 mg, and Chlorthalidone 25 mg, illustrating their relative efficacy across varying baseline systolic blood pressures.*

FDA Label Image

Figure 1.b (Edarbyclor 02)

A line graph showing the percentage of patients with systolic blood pressure below 130 mmHg plotted against baseline systolic blood pressure (mmHg). The graph compares Edarbyclor 40/25 mg, Chlorthalidone 25 mg, and Azilsartan medoxomil 80 mg, depicting that Edarbyclor 40/25 mg achieves the highest percentage reduction across baseline values.*

FDA Label Image

Figure 1.c (Edarbyclor 03)

A line graph showing the percentage of patients with diastolic blood pressure below 90 mmHg versus baseline diastolic blood pressure (mmHg). It compares three treatments: Edarbyclor 40/25 mg, Azilsartan medoxomil 80 mg, and Chlorthalidone 25 mg, with Edarbyclor maintaining the highest percentage across the baseline range.*

FDA Label Image

Figure 1.d (Edarbyclor 04)

This line chart compares the percentage of patients achieving diastolic blood pressure below 80 mmHg at various baseline diastolic blood pressures. Three treatments are shown: Edarbyclor 40/25 mg (solid line), Azilsartan medoxomil 80 mg (dotted line), and Chlorthalidone 25 mg (dashed line), demonstrating their efficacy across the baseline diastolic BP range from 80 to 115 mmHg.*

FDA Label Image

Chemical Structure (Edarbyclor 05)

Chemical structure diagram of the active ingredient in Edarbyclor, showing detailed molecular bonds and specific groups including a potassium ion (K+).*

FDA Label Image

Chemical Structure (Edarbyclor 06)

Chemical structure diagram of Edarbyclor's active ingredient, showing detailed molecular bonds and substituents including a sulfonamide group and chlorine atom attached to a benzene ring.*

FDA Label Image

Figure 2 (Edarbyclor 07)

A pharmacokinetic chart showing fold change and 90% confidence intervals for various population subgroups (age, gender, race, renal impairment, hepatic impairment, pediatric) related to Edarbyclor. The graph plots Cmax and AUC values relative to a reference, with recommendations on dose adjustments, mostly indicating no dose adjustment needed except for severe hepatic impairment and pediatric groups where there is no experience.*

FDA Label Image

Figure 3 (Edarbyclor 08)

A line graph comparing the mean blood pressure change (mm Hg) over 24 hours after dosing for Azilsartan medoxomil 40 mg, Chlorthalidone 12.5 mg, and Edarbyclor 40/12.5 mg. The x-axis shows hours after dosing from 1 to 24, and the y-axis shows mean blood pressure change ranging from 1 to -35 mm Hg. Edarbyclor shows a greater decrease in mean blood pressure compared to the other two treatments throughout the 24-hour period.*

FDA Label Image

Principal Display Panel (40 mg/12.5 mg Tablet Bottle Label)

Edarbyclor 40 mg/12.5 mg tablets packaging label showing the product name and active ingredients Azilsartan Medoxomil and Chlorthalidone. The label includes dosage strength, quantity of 30 tablets, storage instructions, tamper-evident seal warning, and manufacturer information including Zakrzewski and Takeda Ireland. The label advises dispensing and storing in the original container.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.